Immune Effects of Chemorapy, Radiation, and Targeted rapy and Opportunities for Combination with Immunorapy

Seminars in Oncology

Volumn 42, Issue 4, 2015, Pages 601-616

  Wargo, Jennifer A ^a   Reuben, Alexandre ^a   Cooper, Zachary A ^a   Oh, Kevin S ^b   Sullivan, Ryan J ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DABRAFENIB; DACARBAZINE; IPILIMUMAB; PACLITAXEL; TRAMETINIB;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COLON CANCER; EVIDENCE BASED PRACTICE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL SYNAPSE; IMMUNOMODULATION; INTRACELLULAR SIGNALING; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; T LYMPHOCYTE ACTIVATION; TRANSLATIONAL RESEARCH; TUMOR MICROENVIRONMENT; DRUG EFFECTS; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84940376799     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.05.007     Document Type: Review

References (129)

1. D.R. Madden three-dimensional structure of peptide-MHC complexes Ann Rev Immunol 13 1995 587 622
2. O.P. Joffre, E. Segura, A. Savina, and S. Amigorena Cross-presentation by dendritic cells Natu Rev Immunol 12 2012 557 569
3. S.K. Bromley, W.R. Burack, K.G. Johnson, K. Somersalo, T.N. Sims, C. Sumen, and et al. immunological synapse Ann Rev Immunol 19 2001 375 396
4. T. Yokosuka, and T. Saito immunological synapse, TCR microclusters, and T-cell activation Curr Top Microbiol Immunol 340 2010 81 107
5. A. Bernard, Lamy, and I. Alberti two-signal model of T-cell activation after 30 years Transplantation 73 2002 S31 S35
6. C. Caux, B. Vanbervliet, C. Massacrier, and et al. B70/B7-2 is identical to CD86 and is major functional ligand for CD28 expressed on human dendritic cells J Exp Med 180 1994 1841 1847
7. C. Caux, C. Massacrier, B. Vanbervliet, and et al. Activation of human dendritic cells through CD40 cross-linking J Exp Med 180 1994 1263 1272
8. D.W. Lancki, C.S. Hsieh, and F.W. Fitch Mechanisms of lysis by cytotoxic T lymphocyte clones. Lytic activity and gene expression in cloned antigen-specific CD4+ and CD8+T lymphocytes J Immunol 146 1991 3242 3249
9. G. Berke CTL's kiss of death Cell 81 1995 9 12
10. M. Huse T-cell-receptor signaling network J Cell Sci 122 2009 1269 1273
11. P.E. Paz, S. Wang, H. Clarke, X. Lu, D. Stokoe, and A. Abo Mapping Zap-70 phosphorylation sites on LAT (linker for activation of T cells) required for recruitment and activation of signalling proteins in T cells Biochem J 356 2001 461 471
12. K. Hardy, and G. Chaudhri Activation and signal transduction via mitogen-activated protein (MAP) kinases in T lymphocytes Immunol Cell Biol 75 1997 528 545
13. Y. Harada, E. Tanabe, R. Watanabe, and et al. Novel role of phosphatidylinositol 3-kinase in CD28-mediated costimulation J Biol Chem 276 2001 9003 9008
14. G.J. Freeman, A.J. Long, Y. Iwai, and et al. Engagement of PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
15. M.F. Krummel, and J.P. Allison CD28 and CTLA-4 have opposing effects on response of T cells to stimulation J Exp Med 182 1995 459 465
16. D. Bruniquel, N. Borie, S. Hannier, and F. Triebel Regulation of expression of human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II Immunogenetics 48 1998 116 124
17. K. Sakuishi, S.F. Ngiow, J.M. Sullivan, and et al. TIM3FOXP3 regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer Oncoimmunology 2 2013 e23849
18. D. McDermott, C. Lebbe, F.S. Hodi, and et al. Durable benefit and potential for long-term survival with immunorapy in advanced melanoma Cancer Treat Rev 40 2014 1056 1064
19. Z.A. Cooper, V.R. Juneja, P.T. Sage, and et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade Cancer Immunol Res 2 2014 643 654
20. S.S. Legha, S. Ring, A. Bedikian, and et al. Treatment of metastatic melanoma with combined chemorapy containing cisplatin, vinblastine and dacarbazine (CVD) and biorapy using interleukin-2 and interferon-alpha Ann Oncol 7 1996 827 835
21. S.S. Legha, S. Ring, O. Eton, and et al. Development of a biochemorapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma J Clin Oncol 16 1998 1752 1759
22. D.F. McDermott, J.W. Mier, D.P. Lawrence, and et al. A phase II pilot trial of concurrent biochemorapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma Clin Cancer Res 6 2000 2201 2208
23. E. Bajetta, M. Del Vecchio, P. Nova, and et al. Multicenter phase III randomized trial of polychemorapy (CVD regimen) versus same chemorapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma Ann Oncol 17 2006 571 577
24. M.B. Atkins, J. Hsu, S. Lee, and et al. Phase III trial comparing concurrent biochemorapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): A trial coordinated by Eastern Cooperative Oncology Group J Clin Oncol 26 2008 5748 5754
25. A. Alrwas, N.E. Papadopoulos, S. Cain, and et al. Phase I trial of biochemorapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-alpha in patients with metastatic melanoma Melanoma Res 24 2014 342 348
26. A.K. Nowak, R.A. Lake, A.L. Marzo, and et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rar than cross-tolerizing host tumor-specific CD8 T cells J Immunol 170 2003 4905 4913
27. A.K. Nowak, B.W. Robinson, and R.A. Lake Gemcitabine exerts a selective effect on humoral immune response: implications for combination chemo-immunorapy Cancer Res 62 2002 2353 2358
28. R.G. van der Most, A.J. Currie, S. Mahendran, A. Prosser, A. Darabi, B.W. Robinson, and et al. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: A role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemorapy Cancer Immunol Immunor 58 2009 1219 1228
29. M. Jure-Kunkel, G. Masters, E. Girit, and et al. Synergy between chemorapeutic agents and CTLA-4 blockade in preclinical tumor models Cancer Immunol Immunor 62 2013 1533 1545
30. W.J. Lesterhuis, J. Salmons, A.K. Nowak, and et al. Synergistic effect of CTLA-4 blockade and cancer chemorapy in induction of anti-tumor immunity PloS One 8 2013 e61895
31. L. Wu, Z. Yun, T. Tagawa, K. Rey-McIntyre, and M. de Perrot CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during intervals of chemorapy in murine mesolioma Mol Cancer r 11 2012 1809 1819
32. E.M. Hersh, S.J. O'Day, J. Powderly, and et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemorapy-naive patients with advanced melanoma Invest New Drugs 29 2011 489 498
33. J.S. Weber, K.C. Kahler, and A. Hauschild Management of immune-related adverse events and kinetics of response with ipilimumab J Clin Oncol 30 2012 2691 2697
34. C. Robert, L. Thomas, I. Bondarenko, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
35. T.J. Lynch, I. Bondarenko, A. Luft, and et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study J Clin Oncol 30 2012 2046 2054
36. M. Reck, I. Bondarenko, A. Luft, and et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line rapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Ann Oncol 24 2013 75 83
37. S.J. Antonia, J.R. Brahmer, S.N. Gettingger, and et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemorapy (PT-DC) in advanced non-small cell lung cancer (NSCLC) ASCO Annual Meeting 2014 Chicago, IL
38. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
39. P.I. Poulikakos, Y. Persaud, M. Janakiraman, and et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 480 2011 387 390
40. R.J. Sullivan, D.P. Lawrence, J.A. Wargo, K.S. Oh, R.G. Gonzalez, and A. Piris Case records of Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma N Engl J Med 369 2013 173 183
41. A.M. Di Giacomo, P.A. Ascierto, L. Pilla, and et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): An open-label, single-arm phase 2 trial Lancet Oncol 13 2012 879 886
42. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: Next generation Cell 144 2011 646 674
43. K.G. Griewank, R.A. Scolyer, J.F. Thompson, K.T. Flaherty, D. Schadendorf, and R. Murali Genetic alterations and personalized medicine in melanoma: Progress and future prospects J Natl Cancer Inst 2014 106 djt435
44. P.B. Chapman, A. Hauschild, C. Robert, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
45. J.A. Sosman, K.B. Kim, L. Schuchter, and et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
46. C.M. Emery, K.G. Vijayendran, M.C. Zipser, and et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition Proc Natl Acad Sci U S A 106 2009 20411 20416
47. C.M. Johannessen, J.S. Boehm, S.Y. Kim, and et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 2010 968 972
48. C. Montagut, S.V. Sharma, T. Shioda, and et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res 68 2008 4853 4861
49. R. Nazarian, H. Shi, Q. Wang, and et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
50. M.P. O'Connell, K. Marchbank, M.R. Webster, and et al. Hypoxia induces phenotypic plasticity and rapy resistance in melanoma via tyrosine kinase receptors ROR1 and ROR2 Cancer Disc 3 2013 1378 1393
51. F. Sabbatino, Y. Wang, X. Wang, and et al. PDGFRalpha up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation Oncotarget 5 2014 1926 1941
52. E.M. Van Allen, N. Wagle, A. Sucker, and et al. genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma Cancer Disc 4 2014 94 109
53. J. Villanueva, A. Vultur, J.T. Lee, and et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695
54. N. Wagle, C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, P. Pochanard, and et al. Dissecting rapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J Clin Oncol 29 2011 3085 3096
55. N. Wagle, E.M. Van Allen, D.J. Treacy, and et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition Cancer Disc 4 2014 61 68
56. R. Straussman, T. Morikawa, K. Shee, and et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 487 2012 500 504
57. D.T. Frederick, A. Piris, A.P. Cogdill, and et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma Clin Cancer Res 19 2013 1225 1231
58. J.S. Khalili, S. Liu, T.G. Rodriguez-Cruz, and et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma Clin Cancer Res 18 2012 5329 5340
59. C. Liu, W. Peng, C. Xu, Y. Lou, and et al. BRAF inhibition increases tumor infiltration by T cells and enhances antitumor activity of adoptive immunorapy in mice Clin Cancer Res 19 2013 393 403
60. M.P. Smith, B. Sanchez-Laorden, K. O'Brien, and et al. immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha Cancer Disc 4 2014 1214 1229
61. H. Sumimoto, F. Imabayashi, T. Iwata, and Y. Kawakami BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells J Exp Med 203 2006 1651 1656
62. A. Boni, A.P. Cogdill, P. Dang, and et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function Cancer Res 70 2010 5213 5219
63. L.J. Vella, A. Pasam, N. Dimopoulos, and et al. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells Cancer Immunol Res 2 2014 351 360
64. M.K. Callahan, G. Masters, C.A. Pratilas, and et al. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor Cancer Immunol Res 2 2014 70 79
65. J.S. Wilmott, G.V. Long, J.R. Howle, and et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma Clin Cancer Res 18 2012 1386 1394
66. S. Spranger, R.M. Spaapen, Y. Zha, and et al. Up-regulation of PD-L1, IDO, and T(regs) in melanoma tumor microenvironment is driven by CD8(+) T cells Sci Translat Med 5 2013 200ra116
67. D.T. Frederick, Z. Ahmed, Z.A. Cooper, and et al. Stromal fibroblasts contribute to up-regulation of PD-L1 in melanoma after BRAF inhibition Society For Melanoma Congress; 2013; Philadelphia, PA; pp 950-1 2013
68. X. Jiang, J. Zhou, A. Giobbie-Hurder, J. Wargo, and F.S. Hodi activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition Clin Cancer Res 19 2013 598 609
69. Z.A. Cooper, D.T. Frederick, V.R. Juneja, and et al. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes Oncoimmunology 2 2013 e26615
70. R.C. Koya, S. Mok, N. Otte, and et al. BRAF inhibitor vemurafenib improves antitumor activity of adoptive cell immunorapy Cancer Res 72 2012 3928 3937
71. D.A. Knight, S.F. Ngiow, M. Li, and et al. Host immunity contributes to anti-melanoma activity of BRAF inhibitors J Clin Invest 123 2013 1371 1381
72. A. Hooijkaas, J. Gadiot, M. Morrow, R. Stewart, T. Schumacher, and C.U. Blank Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma Oncoimmunology 1 2012 609 617
73. A. Ribas, F.S. Hodi, M. Callahan, C. Konto, and J. Wolchok Hepatotoxicity with combination of vemurafenib and ipilimumab N Engl J Med 368 2013 1365 1366
74. Puzanov I, Callahan M, Linette GP, et al. Phase I study of BRAF inhibitor dabrafenib (D)± MEK inhibitor trametinib (T) in combination with ipilimumab (I) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) 2014 ASCO Annual Meeting; 2014; Chicago, IL.
75. C.L. Corless, and M.C. Heinrich Molecular pathobiology of gastrointestinal stromal sarcomas Ann Rev Pathol 3 2008 557 586
76. V.P. Balachandran, M.J. Cavnar, S. Zeng, and et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through inhibition of Ido Nat Med 17 2011 1094 1100
77. B.I. Rini, S. Halabi, J.E. Rosenberg, and et al. Bevacizumab plus interferon alfa compared with interferon alfa monorapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
78. B.I. Rini, S. Halabi, J.E. Rosenberg, and et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monorapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
79. U.B. Dandamudi, M. Ghebremichael, J.A. Sosman, and et al. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: A Cytokine Working Group (CWG) study J Immunor 36 2013 490 495
80. F.S. Hodi, D. Lawrence, C. Lezcano, and et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma Cancer Immunol Res 2 2014 632 642
81. P.U. Huguenin, S. Kieser, C. Glanzmann, R. Capaul, and U.M. Lutolf Radiorapy for metastatic carcinomas of kidney or melanomas: An analysis using palliative end points Int J Radiat Oncol Biol Phys 41 1998 401 405
82. D.J. Brenner, and J.F. Ward Constraints on energy deposition and target size of multiply damaged sites associated with DNA double-strand breaks Int J Radiat Biol 61 1992 737 748
83. M. Lobrich, P.K. Cooper, and B. Rydberg Non-random distribution of DNA double-strand breaks induced by particle irradiation Int J Radiat Biol 70 1996 493 503
84. S. Cole Long-term effects of local ionizing radiation treatment on Langerhans cells in mouse footpad epidermis J Invest Dermatol 87 1986 608 612
85. R.F. James, S.P. Lake, J. Chamberlain, and et al. Gamma irradiation of isolated rat islets pretransplantation produces indefinite allograft survival in cyclosporine-treated recipients Transplantation 47 1989 929 933
86. J. Wasserman, H. Blomgren, S. Rotstein, B. Petrini, and S. Hammarstrom Immunosuppression in irradiated breast cancer patients: in vitro effect of cyclooxygenase inhibitors. Bull NY Acad Med 65 1989 36 44
87. L. Apetoh, F. Ghiringhelli, A. Tesniere, and et al. Toll-like receptor 4-dependent contribution of immune system to anticancer chemorapy and radiorapy Nat Med 13 2007 1050 1059
88. E.B. Golden, I. Pellicciotta, S. Demaria, M.H. Barcellos-Hoff, and S.C. Formenti convergence of radiation and immunogenic cell death signaling pathways Front Oncol 2 2012 88
89. B. Burnette, and R.R. Weichselbaum Radiation as an immune modulator Semin Radiat Oncol 23 2013 273 280
90. H. El-Saghire, A. Michaux, H. Thierens, and S. Baatout Low doses of ionizing radiation induce immune-stimulatory responses in isolated human primary monocytes Int J Mol Med 32 2013 1407 1414
91. S. Demaria, N. Kawashima, A.M. Yang, and et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer Clin Cancer Res 11 2005 728 734
92. W.H. McBride, C.S. Chiang, J.L. Olson, and et al. A sense of danger from radiation Radiat Res 162 2004 1 19
93. S.H. Hauser, L. Calorini, D.E. Wazer, and S. Gattoni-Celli Radiation-enhanced expression of major histocompatibility complex class I antigen H-2Db in B16 melanoma cells Cancer Res 53 1993 1952 1955
94. E.A. Reits, J.W. Hodge, C.A. Herberts, and et al. Radiation modulates peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunorapy J Exp Med 203 2006 1259 1271
95. M. Hareyama, K. Imai, K. Kubo, and et al. Effect of radiation on expression of carcinoembryonic antigen of human gastric adenocarcinoma cells Cancer 67 1991 2269 2274
96. Y. Lee, S.L. Auh, Y. Wang, and et al. rapeutic effects of ablative radiation on local tumor require CD8+T cells: Changing strategies for cancer treatment Blood 114 2009 589 595
97. C.A. Perez, A. Fu, H. Onishko, D.E. Hallahan, and L. Geng Radiation induces an antitumour immune response to mouse melanoma Int J Radiat Biol 85 2009 1126 1136
98. R.H. Mole Whole body irradiation; radiobiology or medicine? Br J Radiol 26 1953 234 241
99. D.P. Kingsley An interesting case of possible abscopal effect in malignant melanoma Br J Radiol 48 1975 863 866
100. M.A. Postow, M.K. Callahan, C.A. Barker, and et al. Immunologic correlates of abscopal effect in a patient with melanoma N Engl J Med 366 2012 925 931
101. E.F. Stamell, J.D. Wolchok, S. Gnjatic, N.Y. Lee, and I. Brownell abscopal effect associated with a systemic anti-melanoma immune response Int J Radiat Oncol Biol Phys 85 2013 293 295
102. A.M. Grimaldi, E. Simeone, D. Giannarelli, and et al. Abscopal effects of radiorapy on advanced melanoma patients who progressed after ipilimumab immunorapy Oncoimmunology 3 2014 e28780
103. E.B. Golden, S. Demaria, P.B. Schiff, A. Chachoua, and S.C. Formenti An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer Cancer Immunol Res 1 2013 365 372
104. S.E. Cotter, G.P. Dunn, K.M. Collins, and et al. Abscopal effect in a patient with metastatic Merkel cell carcinoma following radiation rapy: Potential role of induced antitumor immunity Arch Dermatol 147 2011 870 872
105. K. Okuma, H. Yamashita, Y. Niibe, K. Hayakawa, and K. Nakagawa Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: A case report J Med Case Rep 5 2011 111
106. D.J. Fairlamb Spontaneous regression of metastases of renal cancer: A report of two cases including first recorded regression following irradiation of a dominant metastasis and review of world literature Cancer 47 1981 2102 2106
107. M.P. MacManus, R.J. Harte, and S. Stranex Spontaneous regression of metastatic renal cell carcinoma following palliative irradiation of primary tumour Irish J Med Sci 163 1994 461 463
108. S. Demaria, B. Ng, M.L. Devitt, and et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated Int J Radiat Oncol Biol Phys 58 2004 862 870
109. H. Liang, L. Deng, S. Chmura, and et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing J Immunol 190 2013 5874 5881
110. H.E. Teulings, E.P. Tjin, K.J. Willemsen, and et al. Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: A case report and immunological analysis Br J Dermatol 168 2013 733 738
111. A. Abood, D.B. Saleh, and D.A. Watt Malignant melanoma and vitiligo: Can radiorapy shed light on subject? J Plastic Reconstruct Aest Surg 62 2009 e119 e120
112. C. Yee, J.A. Thompson, P. Roche, and et al. Melanocyte destruction after antigen-specific immunorapy of melanoma: direct evidence of t cell-mediated vitiligo J Exp Med 192 2000 1637 1644
113. H.E. Teulings, M. Overkamp, E. Ceylan, and et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: A survey among 1307 patients and ir partners Br J Dermatol 168 2013 162 171
114. S.L. Topalian, M. Sznol, D.F. McDermott, and et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 2014 1020 1030
115. S.M. Hiniker, D.S. Chen, S. Reddy, and et al. A systemic complete response of metastatic melanoma to local radiation and immunorapy Translat Oncol 5 2012 404 407
116. S.F. Slovin, C.S. Higano, O. Hamid, and et al. Ipilimumab alone or in combination with radiorapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Ann Oncol 24 2013 1813 1821
117. L.J. Hazard, W.T. Sause, and R.D. Noyes Combined adjuvant radiation and interferon-alpha 2B rapy in high-risk melanoma patients: Potential for increased radiation toxicity Int J Radiat Oncol Biol Phys 52 2002 796 800
118. N.P. Nguyen, B. Levinson, S. Dutta, and et al. Concurrent interferon-alpha and radiation for head and neck melanoma Melanoma Res 13 2003 67 71
119. C. Conill, S. Jorcano, J. Domingo-Domenech, and et al. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients Melanoma Res 17 2007 304 309
120. E. Paul, I. Muller, H. Renner, R.H. Bodeker, and A.J. Cochran Treatment of locoregional metastases of malignant melanomas with radiorapy and intralesional beta-interferon injection Melanoma Res 13 2003 611 617
121. J.R. Lange, A.A. Raubitschek, B.A. Pockaj, and et al. A pilot study of combination of interleukin-2-based immunorapy and radiation rapy J Immunor 12 1992 265 271
122. S.K. Seung, B.D. Curti, M. Crittenden, and et al. Phase 1 study of stereotactic body radiorapy and interleukin-2 - tumor and immunological responses Sci Translat Med 4 2012 137ra74
123. L. Ridolfi, F de Rosa, R. Ridolfi, and et al. Radiorapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose interleukin-2: Evaluation of biomarkers of immunologic and rapeutic response J Translat Med 12 2014 262
124. R.W. Joseph, R.J. Sullivan, R. Harrell, and et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma J Immunor 35 2012 66 72
125. F.O. Smith, S.L. Goff, J.A. Klapper, and et al. Risk of bowel perforation in patients receiving interleukin-2 after rapy with anti-CTLA 4 monoclonal antibody J Immunor 30 2007 130
126. A. Ackerman, O. Klein, D.F. McDermott, and et al. Outcomes of patients with metastatic melanoma treated with immunorapy prior to or after BRAF inhibitors Cancer 120 2014 1695 1701
127. P.A. Ascierto, E. Simeone, V.C. Sileni, and et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from Italian cohort of ipilimumab expanded access program Cancer Invest 32 2014 144 149
128. M.M. Chan, L.E. Haydu, A.M. Menzies, and et al. nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition Cancer 120 2014 3142 3153
129. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133